Prescott General Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-386,000	Closed	-$194K	–	11
2024 Q4	$194K	Hold	386,000	–	–	0.01%	9
2024 Q3	$349K	Sell	386,000 -234,000	-38%	-$212K	0.02%	9
2024 Q2	$618K	Sell	620,000 -1,231,851	-67%	-$1.23M	0.04%	9
2024 Q1	$2.74M	Hold	1,851,851	–	–	0.15%	6
2023 Q4	$2.02M	Hold	1,851,851	–	–	0.12%	7
2023 Q3	$2.19M	Hold	1,851,851	–	–	0.14%	8
2023 Q2	$2.61M	Hold	1,851,851	–	–	0.16%	8
2023 Q1	$2.78M	Hold	1,851,851	–	–	0.22%	8
2022 Q4	$2.17M	Hold	1,851,851	–	–	0.18%	8
2022 Q3	$2.09M	Hold	1,851,851	–	–	0.16%	8
2022 Q2	$2.93M	Hold	1,851,851	–	–	0.2%	8
2022 Q1	$2.85M	Hold	1,851,851	–	–	0.13%	10
2021 Q4	$4.54M	Hold	1,851,851	–	–	0.16%	9
2021 Q3	$4.67M	Hold	1,851,851	–	–	0.16%	9
2021 Q2	$5.28M	Hold	1,851,851	–	–	0.17%	8
2021 Q1	$4.35M	Hold	1,851,851	–	–	0.15%	9
2020 Q4	$3.26M	Hold	1,851,851	–	–	0.14%	9
2020 Q3	$1.73M	Hold	1,851,851	–	–	0.07%	9
2020 Q2	$1.61M	Hold	1,851,851	–	–	0.07%	9
2020 Q1	$1.53M	Hold	1,851,851	–	–	0.13%	8
2019 Q4	$1.65M	Hold	1,851,851	–	–	0.07%	9
2019 Q3	$1.82M	Hold	1,851,851	–	–	0.07%	9
2019 Q2	$2.04M	Hold	1,851,851	–	–	0.08%	9
2019 Q1	$2.43M	Hold	1,851,851	–	–	0.1%	9
2018 Q4	$1.69M	Sell	1,851,851 -264,815	-13%	-$242K	0.07%	10
2018 Q3	$4.35M	Hold	2,116,666	–	–	0.15%	10
2018 Q2	$3.82M	Hold	2,116,666	–	–	0.14%	10
2018 Q1	$4.98M	Hold	2,116,666	–	–	0.21%	10
2017 Q4	$3.98M	Hold	2,116,666	–	–	0.18%	10
2017 Q3	$5.26M	Hold	2,116,666	–	–	0.27%	10
2017 Q2	$5.83M	Hold	2,116,666	–	–	0.31%	11
2017 Q1	$6.39M	Buy	+2,116,666	New	+$6.39M	0.42%	11